Cero Therapeutics Holdings Files Definitive Proxy Statement
Ticker: CEROW · Form: DEF 14A · Filed: Oct 15, 2024 · CIK: 1870404
Sentiment: neutral
Topics: proxy-statement, annual-meeting, corporate-governance
Related Tickers: CRRO
TL;DR
Cero Therapeutics (CRRO) filed its proxy statement for the annual meeting. Shareholders vote soon.
AI Summary
Cero Therapeutics Holdings, Inc. filed its definitive proxy statement on October 15, 2024, for its annual meeting of stockholders. The company, formerly known as Phoenix Biotech Acquisition Corp. until June 30, 2021, is involved in the biological products sector. The filing details information relevant to the upcoming shareholder meeting, including any proposals to be voted on and director nominations.
Why It Matters
This filing provides shareholders with crucial information for the upcoming annual meeting, enabling them to make informed decisions on company matters and director elections.
Risk Assessment
Risk Level: low — This is a routine proxy filing for an annual shareholder meeting, not indicating immediate operational or financial risk.
Key Numbers
- 0001870404 — Central Index Key (Unique identifier for Cero Therapeutics Holdings, Inc.)
- 001-40877 — SEC File Number (SEC filing number for Cero Therapeutics Holdings, Inc.)
Key Players & Entities
- CERO THERAPEUTICS HOLDINGS, INC. (company) — Registrant
- PHOENIX BIOTECH ACQUISITION CORP. (company) — Former company name
- 20241015 (date) — Filing date
- 20241104 (date) — Period of report
- 650-407-2376 (phone_number) — Business phone number
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose is to provide shareholders with information for the annual meeting, including proposals and director nominations, as required by the Securities Exchange Act of 1934.
When was Cero Therapeutics Holdings, Inc. formerly known as Phoenix Biotech Acquisition Corp.?
The company's name was changed from Phoenix Biotech Acquisition Corp. on June 30, 2021.
What is the business address of Cero Therapeutics Holdings, Inc.?
The business address is 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO, CA 94080.
What is the SIC code for Cero Therapeutics Holdings, Inc.?
The Standard Industrial Classification (SIC) code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
On what date was this definitive proxy statement filed?
This definitive proxy statement was filed on October 15, 2024.
Filing Stats: 3,820 words · 15 min read · ~13 pages · Grade level 15.6 · Accepted 2024-10-15 08:47:07
Key Financial Figures
- $0.0001 — g shares of our common stock, par value $0.0001 per share (“Common Stock”
Filing Documents
- ea0217341-01.htm (DEF 14A) — 745KB
- tcero_logo.jpg (GRAPHIC) — 50KB
- tproxy_001.jpg (GRAPHIC) — 1487KB
- tproxy_002.jpg (GRAPHIC) — 1225KB
- 0001213900-24-087416.txt ( ) — 4551KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT   9 PROPOSAL NO. 1: REVERSE STOCK SPLIT PROPOSAL   11 PROPOSAL NO. 2: NASDAQ STOCK ISSUANCE PROPOSAL   21 PROPOSAL NO. 3: PLAN SHARE INCREASE PROPOSAL   23 PROPOSAL NO. 4: ADJOURNMENT PROPOSAL   30
DESCRIPTION OF CAPITAL STOCK
DESCRIPTION OF CAPITAL STOCK   31 STOCKHOLDER PROPOSALS   45 STOCKHOLDER COMMUNICATIONS   45 HOUSEHOLDING   45 SOLICITATION OF PROXIES   46 ANNUAL REPORT   46 OTHER MATTERS   46 WHERE YOU CAN FIND ADDITIONAL INFORMATION   46 i Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This proxy statement (this “proxy statement”) contains forward -looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this proxy statement, including statements regarding the Company’s future results of operations and financial position, business strategy, drug candidates, planned preclinical studies and clinical trials, results of preclinical studies, clinical trials, research and development (“R&D”) costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward -looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company’s control and may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward -looking statements. In some cases, you can identify forward -looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “